AlderBrook Inc – Trademark Portfolio
Entity Type: 03
AlderBrook Inc holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 9 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include OMNIOS, HCFOCUS, OBG LIVE, OBG PROJECT, and OMNIOS HEALTH. The owner is based in NEW YORK, NY.
105 W 86th St #551
NEW YORK, NY 10024
Showing of trademarks Trademarks
Trademark Classifications
AlderBrook Inc's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does AlderBrook Inc have?
AlderBrook Inc has 13 U.S. trademarks filed with the USPTO. Of these, 8 registered, 4 abandoned, 1 cancelled.
What trademark classes does AlderBrook Inc file in?
AlderBrook Inc files trademarks across 3 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 35 (Advertising & Business), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are AlderBrook Inc's most well-known trademarks?
AlderBrook Inc's registered trademark portfolio includes well-known marks such as OMNIOS, HCFOCUS, OBG LIVE, OBG PROJECT, and OMNIOS HEALTH. These are among 8 currently registered trademarks in the portfolio.
What is AlderBrook Inc's trademark registration success rate?
AlderBrook Inc has a 62% trademark registration rate, with 8 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.